Clinical Trial

Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multi-center, phase I/II study to determine the efficacy and safety of CRC01 in adult patients with relapsed or refractory large B-cell lymphoma and B-cell Acute Lymphoblastic Leukemia.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-04-05; most recent amendment 2026-06-29.
Trial Details
NCT Number NCT04836507
Lead Sponsor Curocell Inc.
Conditions Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal Large B-Cell Lymphoma (PMBCL), High-grade B-cell Lymphoma, Transformed Follicular Lymphoma (TFL), ALL (Acute B-Lymphoblastic Leukemia)
Enrollment 91 participants
Start Date 2021-03-02
Primary Completion 2030-08-15 (estimated)
Study Completion 2030-09-26 (estimated)
Updated on ClinicalTrials.gov 2026-07-01